Target intelligence / Profile preview

D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Peptidoglycan component, Glycopeptide binding site, Other
01

Overview

The D-alanyl-D-alanine (D-Ala-D-Ala) terminus is a critical structural motif found at the end of the pentapeptide chain of peptidoglycan precursors, such as Lipid II, in the bacterial cell wall [1, 2]. It serves as the essential substrate for penicillin-binding proteins (PBPs), which catalyze the cross-linking of peptidoglycan strands to provide structural integrity to the bacterial cell [5, 18]. Glycopeptide antibiotics, most notably vancomycin, exert their bactericidal effect by forming high-affinity hydrogen bonds with this specific dipeptide motif [2, 6]. This binding sterically blocks the enzymes responsible for polymerization (transglycosylation) and cross-linking (transpeptidation), leading to cell wall instability and osmotic lysis [2, 15]. Resistance to drugs targeting this site typically involves the metabolic reprogramming of the precursor to terminate in D-alanyl-D-lactate or D-alanyl-D-serine, which significantly reduces antibiotic binding affinity [17, 19, 20]. Because this target is unique to bacteria and absent in human cells, it provides a high degree of selectivity for antimicrobial therapy [14, 15].

Other names
Lipid II D-Ala-D-Ala terminusPeptidoglycan pentapeptide terminusAcyl-D-alanyl-D-alanineD-alanyl-D-alanine dipeptidePeptidoglycan precursor terminus
02

Mechanism of action

Inhibition of cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, sterically hindering transpeptidase and transglycosylase enzymes.

03

Biological functions

Bacterial cell wall synthesisPeptidoglycan cross-linkingSubstrate for transpeptidasesOther
04

Disease associations

Infection
05

Safety considerations

Antibiotic resistance developmentNephrotoxicityOtotoxicityRed man syndrome
06

Interacting drugs

Vancomycin

5 more in the full profile.

07

Biomarkers

VanA genotypeVanB genotypeVanC genotypeMinimum Inhibitory Concentration (MIC)D-Ala-D-Lac presence

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus (D-Ala-D-Ala) (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call